DBV Technologies | DBVT - Current Assets


DBV Technologies reported $88.88M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amarin USD 649.88M 21.55M Dec/2025
BioCryst Pharmaceuticals USD 404.35M 48.66M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
DBV Technologies USD 88.88M 32.36M Sep/2025
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
Galectin Therapeutics USD 27.29M 1.83M Jun/2024
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
Insmed USD 1.79B 137.6M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
United Therapeutics USD 3.7B 208.5M Dec/2025